Arcellx Inc Asset Resilience Ratio
Arcellx Inc asset resilience ratio. Arcellx Inc (ACLX) has an Asset Resilience Ratio of 61.27% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ACLX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Arcellx Inc (2020–2025)
Asset resilience ratio of Arcellx Inc from 2020 to 2025. This chart shows how Arcellx Inc's Asset Resilience Ratio has changed over time. See ACLX FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Arcellx Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Arcellx Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $370.07 Million | 61.27% |
| Total Liquid Assets | $370.07 Million | 61.27% |
Asset Resilience Insights
- Very High Liquidity: Arcellx Inc maintains exceptional liquid asset reserves at 61.27% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arcellx Inc Industry Peers by Asset Resilience Ratio
Compare Arcellx Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Arcellx Inc Asset Resilience Ratio by Year (2020–2025)
Arcellx Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Arcellx Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 61.27% | $370.07 Million | $603.99 Million | -6.45pp |
| 2024-12-31 | 67.72% | $481.70 Million | $711.33 Million | +30.46pp |
| 2023-12-31 | 37.26% | $307.43 Million | $825.13 Million | -23.50pp |
| 2022-12-31 | 60.75% | $190.66 Million | $313.82 Million | +3.46pp |
| 2021-12-31 | 57.29% | $73.78 Million | $128.78 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $57.69 Million | -- |
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more